ESMO 2023 | Non-WT BRCA associated with inferior prognosis in patients with metastatic prostate cancer

Arun Azad, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of a study observing circulating tumor DNA (ctDNA) in patients with metastatic prostate cancer to identify biomarkers associated with poor patient prognosis. It was found that mutations or deletions in BRCA and other associated DNA repair mechanisms predicted inferior patient prognosis, with treatment responses to conventional chemotherapies and androgen receptor pathway inhibitors being reduced. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.